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Background: Recently, it has been shown that 5-fluorouracil (5-FU) with a strong dihydropyrimidine dehydrogenase
(DPD) inhibitor elicits a significant response in bladder cancer with a high level of DPD. However, only a few studies
investigated the association between the level of the enzyme that regulates the metabolism of 5-FU and prognosis
in bladder cancer. Furthermore, to our knowledge, there has also been no such report in T1G3 bladder tumors
treated with BCG. Therefore, we evaluated enzymes that regulate the metabolism of 5-FU in T1G3 tumors treated
with BCG immunotherapy using the Danenberg tumor profile (DTP) method, a highly accurate measurement of
RNA from paraffin-embedded specimens.
Methods: This study included 28 patients with T1G3 bladder cancer, each of whom underwent complete
transurethral tumor resection and BCG intravesical instillation at our institution. The median follow-up period was
39 months (range, 3 to 159 months). The DTP method was used to analyze the mRNA expression of 3 enzymes
related to 5-FU: DPD, orotate phosphoribosyltransferase (OPRT), and thymidylate synthase (TS).
Results: Among the 28 patients, 13 developed recurrences (46.4%) and 5 experienced disease progression (17.9%).
An elevated DPD mRNA level was significantly associated with recurrence (p = 0.048) and progression (p = 0.045).
However, TS and OPRT mRNA levels were not significantly associated with any other clinical features or outcomes.
Furthermore, the high DPD group had a significantly lower recurrence-free survival rate than the low DPD group
(p = 0.047). Among patients with low DPD, the 2- and 5-year recurrence-free survival rates were 88.9% and 74.1%,
respectively; while among patients with high DPD, the corresponding rates were 61.3% and 36.8%, respectively.
TS and OPRT were not significantly associated with recurrence-free survival rates.
Conclusion: DPD is significantly associated with recurrence and progression among T1G3 bladder cancer patients
treated with BCG.
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5-Fluorouracil (5-FU) has been used clinically to treat
various cancers such as gastric, colon and bladder cancers.
Previous studies have shown that enzymes that regulate
the metabolism of 5-FU are significantly associated with
the prognosis of bladder cancer, based on isotope labeling
analyses [1-3]. Such enzymes include thymidylate synthase
(TS), which is a target enzyme of 5-FU; dihydropyrimidine
dehydrogenase (DPD), which degrades the majority of
5-FU; and orotate phosphoribosyltransferase (OPRT),
which is the principal enzyme that converts 5-FU di-
rectly into an active antitumor metabolite. Furthermore,
Mizutani et al. have demonstrated a significant association
between enzymes that regulate the metabolism of 5-FU
and tumor recurrence in cases of low-grade non-muscle-
invasive bladder cancer [4]. Their report showed that
patients with both low TS and high DPD activities had
substantially higher rates of recurrence-free survival (RFS)
than other patients. Accordingly, they suggested that a
combination of TS and DPD activities might provide a sig-
nificant prognostic indicator for low-grade non-muscle-
invasive bladder cancer. Actually, uracil/tegafur (UFT),
which is a 5-FU-based agent, has been shown to be effec-
tive in cases of low-grade non-muscle-invasive bladder
cancer and S-1, a novel 5-FU-based agent with a strong
DPD inhibitor, has a significant response compared to
UFT in bladder cancer with a high level of DPD [5,6].
However, to the best of our knowledge, no study has ever
evaluated the association between enzymes that regulate
the metabolism of 5-FU and cancer outcomes for cases of
high-grade non-muscle-invasive bladder cancer.
In general, bladder cancer is clinically characterized by a
high rate of recurrence and has a poor prognosis after
tumors invade the muscle layer [7-10]. T1G3 bladder
tumors have a particularly high risk of recurrence and
progression to muscle invasion or metastatic disease.
Intravesical Bacillus Calmette-Guerin (BCG) immuno-
therapy is a highly successful therapy for preventing tumor
recurrence in cases with non-muscle invasive bladder can-
cer, but is not significantly associated with reduced disease
progression [11,12]. In practice, approximately 50% of
T1G3 patients who receive BCG therapy ultimately
develop recurrence, and half the patients who develop
recurrence face disease progression that necessitates total
cystectomy [13]. However, to our knowledge, few studies
have investigated prognostic predictors for cases of T1G3
bladder tumors treated with BCG.
Danenberg et al. developed a methodology to evaluate
gene expression in formalin-fixed paraffin embedded
(FFPE) specimens [14]. This newly developed metho-
dology has several advantages over previous methods,
specifically providing more accuracy and practicality.
There are various methods for measuring the levels of
enzymes that regulate the metabolism of 5-FU. Amongthem, standard polymerase chain reaction (PCR), bio-
chemical assays, and most other conventional techniques
are not practical because these measurements usually re-
quire fresh samples. In fresh frozen samples of cancer,
contamination with cancer stroma and even normal tis-
sue cannot be avoided. Therefore, previous studies of en-
zymes that regulate the metabolism of 5-FU have relied
on immunohistochemistry, which can be evaluated from
FFPE specimens, but are less accurate and precise.
Meanwhile, the Danenberg tumor profile (DTP) method
provides improved accuracy because it involves mea-
suring gene expression from FFPE specimens [15]. Fur-
thermore, laser capture microdissection (LCM) provides
selective isolation of a defined cell population from
heterogenous tissue sections [16]. Thus, DTP with LCM
is clinically relevant and can provide accurate informa-
tion for predicting the outcomes of patients with cancer.
In the present study, using DTP with LCM, we eva-
luated the association of enzymes that regulate the meta-
bolism of 5-FU (including DPD, TS, and OPRT) with the
clinical characteristics and outcomes, with a special focus
on T1G3 bladder cancer treated with BCG therapy.
Methods
Patient population
Surgical specimens from 45 patients who had been sur-
gically treated for primary T1G3 bladder tumor with
complete transurethral resection at Keio University Hos-
pital from 1993 to 2006 were examined. Patients with an
upper urinary tract tumor at the time of diagnosis or in-
complete clinical data were excluded from the study.
Seventeen patients who did not receive adjuvant BCG
treatment were also excluded. The final study sample was
composed of 28 patients with T1G3 tumors who had
received BCG therapy. The regimen consisted of weekly
BCG instillations at a dose of 80 mg for the Tokyo strain,
or 81 mg for the Connaught strain, for 6–8 weeks.
Follow-up consisted of cystoscopy with cytology,
which was performed every 3 months for the first 2
years, every 6 months for the next 3 years, and annually
thereafter. Distant metastasis and upper urinary tract
tumor recurrence were evaluated by performing intra-
venous urography, ultrasonography, or computed tom-
ography scanning. Such evaluations were performed
every 1 or 2 years for 5 years after the initial treatment.
Recurrence was defined as a new tumor occurring in the
bladder, and progression was defined as muscular inva-
sion (stage T2 or higher) or metastatic disease.
The study itself was approved by the Keio University
Ethics Committee. All specimens were fixed in 10%
formalin and embedded in paraffin, and all slides were
re-reviewed by an uropathologist. Tumors were staged
according to the American Joint Committee on Cancer–
Union Internationale Contre le Cancer TNM classification.
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WHO/International Society of Urology Pathology con-
sensus classification [17]. Lymphovascular invasion was
defined as the presence of tumor cells within an
endothelium-lined space without underlying muscular
walls.
Microdissection of primary tumors
Sections (10-μm thick) were obtained from areas iden-
tified as having the highest tumor concentration and
then mounted on uncoated glass slides. For histology,
representative sections were stained with hematoxylin
and eosin according to the standard method. Before
microdissection, sections were deparaffinized in xy-
lene for 10 minutes and hydrated with ethanol solu-
tions of 100%, 95%, and finally 70%. Sections were
then washed in H2O for 30 seconds, stained with
nuclear fast red (NFR, American MasterTech Scien-
tific, Lodi, CA) for 20 seconds, and rinsed again in
H2O for 30 seconds. Finally, the samples were de-
hydrated with ethanol solutions of 70%, 95%, and
100% for 30 seconds each, followed by xylene again for
10 minutes. The slides were then completely air-dried.
The sections of interest were selectively isolated by
using LCM (P.A.L.M. Microsystem, Leica, Wetzlar,
Germany), according to the standard procedure [18].
Cancer cells and cancerous stroma of the sample were
dissected by using the LCM technique. At least 25 mm2
of tumor tissue and stromal tissue were collected from
each FFPE block.
RNA Extraction and analysis of mRNA level
The dissected tissue samples were transferred to reaction
tubes containing 400 μL of 4 M dithiothreitol (DTT)-
GITC/sarc (4 M guanidinium isothiocyanate, 50 mM
Tris–HCl, 25 mM EDTA) (Invitrogen; No. 15577–018).
The blinded tissue samples (400 μL) designated for extrac-
tion were placed in a 0.5 mL thin-walled tube. The sam-
ples were homogenized and an additional 60 μL of GITC/
sarc solution was added. They were heated at 92°C for 30
minutes and then transferred to a 2 mL centrifuge tube.
Fifty μL of 2 M sodium acetate, pH 4.0, were added,
followed by 600 μL of freshly prepared phenol/chloro-
form/isoamyl alcohol (250:50:1). The tubes were vortexed
for 15 seconds, placed on ice for 15 minutes, and then
centrifuged at 13,000 rpm for 8 minutes in a chilled (8°C)
centrifuge. The upper aqueous phase was carefully re-
moved and placed in a 1.5 mL centrifuge tube. Glycogen
(10 μL) and 300–400 μL of isopropanol were added, and
the samples were vortexed for 10–15 seconds. The tubes
were chilled at −20°C for 30–45 minutes to precipitate the
RNA. The samples were then centrifuged at 13,000 rpm
for 7 minutes in an 8°C centrifuge. The supernatant was
poured off and 500 μL of 75% ethanol was added. Thetubes were again centrifuged at 13,000 rpm for 6 minutes
in a chilled (8°C) centrifuge. The supernatant was then
carefully poured off, so as not to disturb the RNA pellet,
and the samples were quick-spun for another 15 seconds
at 13,000 rpm. The remaining ethanol was removed and
the samples were left to air-dry for 15 minutes. The pellet
was resuspended in 50 μL of 5 mM Tris. Finally, the
cDNA was prepared according to the method of Lord and
colleagues [19].
Quantification of the 3 genes-of-interest (TS, DPD, and
OPRT) as well as an internal reference gene (β-actin) was
performed using a fluorescence-based real-time detection
method (ABI PRISM 7900 Sequence detection System,
TaqMan®, Perkin-Elmer (PE) Applied Biosystem, Foster
City, CA). The PCR reaction mixture consisted of 1,200
nM of each primer, 200 nM of probe, 0.4 U of AmpliTaq
gold polymerase, 200 nM each of dATP, dCTP, dGTP and
dTTP, 3.5 mM of MgCl2 and 1 × Taqman buffer A con-
taining a reference dye. The final volume of the reaction
mixture was 20 μL (all reagents were obtained from PE
Applied Biosystems, Foster City, CA). Cycling conditions
were 50°C for 2 minutes, 95°C for 10 minutes, followed by
46 cycles of 95°C for 15 seconds and 60°C for 1 minute.
The following primers and probe sequences were used: TS
primers: GCCTCGGTGTGCCTTTCA and CCCGTGAT
GTGCGCAAT, probe 6FAM (carboxyfluorescein)-TCG
CCAGCTACGCCCTGCTCA; DPD primers: AGGACG
CAAGGAGGGTTTG and GTCCGCCGAGTCCTTACT
GA, probe 6FAM-CAGTGCCTACAGTCTCGAGTCT
GCCAGTG; OPRT primers: TAGTGTTTTGGAAAC
TGTTGAGGTT and CTTGCCTCCCTGCTCTCTGT,
probe 6FAM-TGGCATCATTGACCTTCAAGCCCTCC
T; β-actin primers: TGAGCGCGGCTACAGCTT and
TCCTTAATGTCACGCACGATTT, probe 6FAM-ACCA
CCACGGCCGAGCGG. TaqMan® measurements yield Ct
values that are inversely proportional to the amount of
cDNA in the tube. For example, a higher Ct value means
that more PCR cycles are required to reach a certain level
of cDNA detection. Gene expression values (relative
mRNA levels) are expressed as ratios (differences between
the Ct values) between the gene of interest and an internal
reference gene (β-actin). This reference gene provided the
baseline measurement for the amount of RNA isolated
from a specimen.
Statistical analysis
All data are presented as the mean ± standard error (SE).
Associations between enzymes that regulate the me-
chanism of 5-FU and clinicopathological features were
assessed using the Mann–Whitney U-test or the chi-
square test. RFS was estimated using the Kaplan–Meier
method, and analyzed with the log-rank test. As des-
cribed previously [20], continuous pretreatment clinical
measurements were analyzed as dichotomous variables
Table 1 Clinical characteristics in T1G3 patients treated
with BCG
Overall
Age, mean ± SE 66.9 ± 2.3
Gender, men/women 23 (82.1%)/5 (17.9%)
Concomitant CIS 7 (25.0%)
Multiple disease 19 (67.9%)




Disease specific death 0 (0.0%)
SE: standard error; CIS: carcinoma in situ; LVI: lymphovascular invasion.
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lows. The value that best discriminated between good
and poor survival (i.e., which had the most significant
P value in a log-rank test) was found by testing all pos-
sible cutpoints. All such cutpoints were then rounded to
clinically relevant (i.e., convenient) values. The level of
statistical significance was set at p < 0.05. These analyses
were performed with the SPSS statistical software pack-
age, version 16.0 (SPSS: An IBM Company, Chicago, IL).Table 2 The association between clinical variables and 5-FU r
TS (mean ± S
Age
Less than 70 (n = 14) 10.58 ± 2.12
70 or greater (n = 14) 8.23 ± 1.01
p value 0.664
Gender
Men (n = 23) 9.55 ± 1.34
Female (n = 5) 8.16 ± 1.21
p value 0.748
Concomitant CIS
Yes (n = 7) 10.80 ± 2.23
No (n = 21) 8.94 ± 1.25
p value 0.341
Multiple disease
Yes (n = 19) 8.98 ± 1.22
No (n = 9) 10.05 ± 2.26
p value 0.770
LVI
Yes (n = 18) 9.64 ± 1.33
No (n = 10) 8.72 ± 1.93
p value 0.547
SE: standard error; CIS: carcinoma in situ; LVI: lymphovascular invasion; TS: thymidyla
phosphoribosyl transferase.Results
Clinical characteristics in overall patients
The median duration of follow-up was 39 months
(range, 3 to 159 months), and median patient age was 71
years (range, 34 to 83 years). Of the 28 patients treated
with BCG, 13 developed recurrence (46.4%) and 5 expe-
rienced disease progression (17.9%). Of the 28 patients
treated with BCG, 1 died of a cause other than bladder
cancer, and no patient died of bladder cancer (Table 1).
Associations between the clinical variables and enzymes
that regulate the metabolism of 5-FU
The mean ± SE mRNA levels of TS, DPD, and OPRT in
overall T1G3 samples analyzed (n = 28) were 9.40 ± 1.62,
1.21 ± 0.26, and 1.99 ± 0.21, respectively. There were no
significant differences between any of the clinical vari-
ables and levels of enzymes that regulate the metabolism
of 5-FU (Table 2).
Associations between clinical outcomes and enzymes that
regulate the metabolism of 5-FU
Tumor recurrence was observed in 13 patients (46%)
during follow-up. In overall T1G3 samples, the mean ±
SE mRNA level of DPD was 1.69 ± 0.42 in the re-
currence group, which was significantly higher than theelated enzymes in T1G3 patients treated with BCG
E) DPD (mean ± SE) OPRT (mean ± SE)
1.02 ± 0.23 1.91 ± 0.21
1.44 ± 0.26 2.08 ± 0.23
0.268 0.964
1.35 ± 0.21 1.88 ± 0.15
0.87 ± 0.34 2.18 ± 0.44
0.123 0.748
0.64 ± 0.21 2.58 ± 0.37
1.31 ± 0.21 1.95 ± 0.15
0.057 0.054
1.57 ± 0.38 1.77 ± 0.17
1.12 ± 0.18 2.26 ± 0.29
0.534 0.130
1.03 ± 0.19 1.91 ± 0.19
1.64 ± 0.32 2.09 ± 0.23
0.055 0.817
te synthase; DPD: dihydropyrimidine dehydrogenase; OPRT: orotate
Figure 1 Comparison of 5-FU related enzyme mRNA expressions between patients with and without recurrence/progression. (A) The
relative TS DPD and OPRT mRNA expressions between patients with and without recurrence; bars, +SE. (B) The relative TS DPD and OPRT mRNA
expressions between patients with and without progression; bars, +SE.
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(Figure 1A).
Stage progression was observed in 5 patients (18%). The
mean ± SE mRNA levels of DPD were 1.88 ± 0.68 in the
progression group, which was significantly higher than the
mean level in the non-progression group (0.98 ± 0.28)
(Figure 1B). However, TS and OPRT levels were not
significantly associated with recurrence or progression
(Figure 1A and B).
When DPD levels were discretized into two groups (as
described in our Methods and previously [20]), the high
DPD group (DPD ≥ 0.5) had a significantly lower RFSFigure 2 Kaplan-Meier curves of recurrence-free survival of the patient
curves of recurrence-free survival according to TS, DPD and OPRT expressiorate than the low DPD group (DPD < 0.5) (p = 0.047)
(Figure 2). Furthermore, the low DPD group had 2- and
5-year RFS rates of 88.9% and 74.1%, respectively, while
the high DPD group had corresponding RFS rates of
61.3% and 36.8%. We found no significant relationship
between RFS rates and TS or OPRT (Figure 2).
Discussion
Approximately 50% of patients who have T1G3 bladder
cancer and receive BCG therapy survive without recur-
rence. On the other hand, half of the patients who de-
velop recurrence also experience disease progression tos with high and low 5-FU related enzyme expressions. Kaplan-Meier
ns; bars, ± SE.
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bladder cancer have a malignant potential that cannot
be prevented by using BCG therapy. However, no
marker has been identified that can reliably predict the
outcome of patients with T1G3 who receive BCG
therapy. To our knowledge, only a few studies have eva-
luated significant predictors of clinical outcomes for
T1G3 bladder cancers among patients treated with BCG.
Lebret et al. have demonstrated that p53 is not a viable
indicator of recurrence among patients with T1G3
bladder cancer [21]. Meanwhile, Alvarez-Múgica et al.
found that high levels of myopodin methylation expres-
sion were significantly associated with increased rates of
recurrence and progression among these patients, as
well as shorter disease-specific survival times [22].
Previous studies found that enzymes that regulate the
metabolism of 5-FU (such as TS, DPD, and OPRT) were
significant prognostic factors for urothelial carcinoma
(UC) of the bladder and upper urinary tract [1,6,23].
However, to our knowledge, no previous report has fo-
cused on patients who received BCG therapy for T1G3
bladder cancer. Furthermore, previous reports have mea-
sured the levels of enzymes that regulate the metabolism
of 5-FU by using isotope labeling or immunohistoche-
mistry, which provide less accurate measurements than
the DTP method [15]. Therefore, we used the DTP
method to evaluate associations between DPD levels and
prognosis among patients who received BCG for T1G3
bladder cancer and found that DPD mRNA was a
significant predictor of recurrence and progression
among these patients.
In previous reports on patients with UC, DPD expres-
sion was not a significant prognostic factor [2,6]. Mizutani
et al. found that patients with high DPD had a lower RFS
rate than patients in the low DPD group, although the dif-
ference was not statistically significant [2]. However, it has
also been reported that DPD expression is significantly as-
sociated with tumor grade, perhaps suggesting that UC
cells with high DPD expression have malignant potential
[2,6]. Another study demonstrated a significant relation-
ship between the combination of TS and DPD levels and
RFS rates in grade 1 and 2 non-muscle-invasive bladder
cancer (Ta, T1). Specifically, patients with both low TS
and high DPD activities had a significantly greater RFS
rate than patients with either higher TS or lower DPD
activities [4]. However, these previous reports did not
assess these relationships among patients treated with
BCG for T1G3 bladder cancer.
Our results demonstrate that a high DPD level is a sig-
nificant prognostic factor among patients treated with
BCG for T1G3 bladder cancer. Therefore, our results
suggest that a DPD inhibitor could potentially be a key
agent for successfully treating cases of T1G3 bladder
cancer that are resistant to BCG. Previous studiesindicated that 5-FU might be a key agent because TS, a
target enzyme of 5-FU, was significantly associated with
tumor stage, grade, and prognosis in UC [1,6,23]. Based
on the results of previous studies and the present study,
5-FU based agents with a strong DPD inhibitor such as
UFT and S-1 might be a novel treatment for T1G3
bladder cancer patients treated with BCG. Therefore,
clinical trials should be performed in the future.
The potential limitations of our study are related to its
retrospective design and the relatively small sample size.
As a result of the small sample size, we were unable to
perform multivariate analyses. Future studies could
explore the details of the mechanism by which higher
DPD levels influence resistance to BCG therapy.
Conclusion
In conclusion, the mRNA level of DPD is significantly
associated with tumor recurrence as well as stage pro-
gression in patients with T1G3 bladder cancer who re-
ceive adjuvant BCG therapy. The DPD expression level
in tumor tissue might be a strong bio-marker in T1G3
cancer patients receiving BCG therapy.
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